Home > Result Summaries: Compounds > Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine Result Summaries: Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine GSKStudy ID Phase Title Summary (Download) 100406/004 phase 3 A phase III, double-blinded, randomized, multicenter, clinical study to assess the safety and immunogenicity of GSK Biologicals' Tdap 0.3 mg candidate vaccine when given as a booster dose to healthy school children and adolescents (9-13 years of age), previously vaccinated with a 5th consecutive dose of acellular pertussis-containing vaccine, in studies APV-118 or APV-120 (5 citation(s)) 104154 phase 4 Open, prospective study of the safety of GSK Biologicals' Boostrix® (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed) administered to a cohort of adolescents in a US Health Maintenance Organization (HMO) (1 citation(s)) 105753 phase 4 Safety & immunogenicity of a booster dose of dTPa vaccine (Boostrix®) co-admnd. with Aventis Pasteur’s meningococcal (serogroups A, C, Y and W-135) polysaccharide vaccine (Menactra™) vs admn. of either vaccine alone in healthy adolescents (2 citation(s)) 106316 phase 3 A study to evaluate immunogenicity and safety of Boostrix compared to Adacel when administered as a booster vaccination in adults aged 19 to 64 years of age (1 citation(s)) 106323 phase 3 A study to evaluate immunogenicity and safety of Boostrix when co-administered with Fluarix in subjects 19 years of age and older (2 citation(s)) 107924 phase 3 Open, booster vaccination study to assess safety and reactogenicity of GSK Biologicals’ dTpa vaccine (Boostrix) when administered to healthy chinese children 6-8 years of age. (1 citation(s)) 108638 phase 3 Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals’ Boostrix (dTpa) vaccine and the Chinese DT vaccine, when administered as booster vaccination in healthy children aged 6-8 years (1 citation(s)) 110080 phase 3 A phase IIIb, controlled, multicenter study to evaluate antibody persistence at 1, 3, 5 and 10 years following administration of a single dose of Tdap vaccine to healthy subjects, 19 years of age and older in the study 106316 (0 citation(s)) 110804 phase 4 Evaluation of GSK Bio's dTpa booster vaccine in adults, given 10 years after previous dTpa boosting. (5 citation(s)) 110806 phase 4 Evaluation of GSK Bio’s dTpa booster vaccine in young adults 10 years after previous dTpa boosting. (7 citation(s)) 111413 phase 3 Evaluation of GSK Biologicals’ Boostrix® vaccine when compared with Decavac™ in adults aged 65 years or older. (2 citation(s)) 113055 phase 4 Evaluation of GSK Biologicals’ Boostrix™ in healthy adults, 10 years after previous booster vaccination (0 citation(s)) 263855/001 Phase 3 Single-blind, randomised clinical study to assess and compare the immunogenicity and reactogenicity of the SB Bios’ dTpa, Pa and pa vaccines, and 2 commercial Td vaccines when administered as a booster dose to healthy adolescents, previously vaccinated with the DTP whole cell vaccine (DTPw) (1 citation(s)) 263855/002 phase 3 Single-blind, clinical study of the immunogenicity and reactogenicity of SB Biologicals’ dTpa, pa vaccines and a Td vaccine, given as a booster dose to healthy adults, from the age of 18 years onwards (6 citation(s)) 263855/004 Phase 3 Randomised clinical study of the consistency of three lots of SB Bios’ dTpa vaccine in terms of immunogenicity and reactogenicity, and of the immunogenicity and reactogenicity of SB Bios’ pa vaccine and Lederle’s Td vaccine when administered as a booster dose to healthy adolescents(10-14 years old) (2 citation(s)) 263855/012 Phase 3 Single-blind clinical study of the immunogenicity and reactogenicity of GSK Biologicals dTpa, pa vaccines and a Tdvaccine, given as a booster dose to healthy adults, from the age of 18 years onwards (5 citation(s)) 263855/014 phase 3 A phase III, double-blind, randomized, single vaccination study of SmithKline Beecham Biologicals’ reduced antigen content diphtheria-tetanus-acellular pertussis and combined diphtheria-tetanus-whole cell Bordetella pertussis vaccines in healthy children. (0 citation(s)) 263855/017 Phase 3 Open, five-year immunogenicity follow-up of subjects who previously received GSK Biologicals dTpa vaccine or GSKBiologicals pa vaccine and Lederles Td vaccine at 10 to 14 years of age in study 263855/004 (EXT: dTpa-004) (3 citation(s)) 263855/019 Phase 4 Open, non-randomized, phase IV study to evaluate immunogenicity and safety of GSK Bios’ dTpa vaccine when administered as single dose to healthy adolescents in their 11th to 18th year of life who were not previously vaccinated against pertussis and have anti-PT antibody titers < 20 EL.U/ml (2 citation(s)) 263855/020 Phase 3 An open, phase III, single center study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals’ dTpa vaccine administered as a single-dose booster in healthy adults aged ( 18 years. (2 citation(s)) 263855/028 Phase 4 Single-blind, randomized, phase IV clinical trial to compare the immunogenicity of GSK Biologicals’ dTpa vaccine (Boostrix™) and Aventis Pasteur MSD’s tetanus toxoid vaccine (Tetavax®), ten days after vaccination of healthy adults 18 years of age and older (3 citation(s)) 263855/029 Phase 2 Observer-blind, randomized, phase II clinical trial to assess the immunogenicity and safety of one dose of three formulations of GSK Biologicals’ dTpa vaccine containing 0.5 mg, 0.3 mg and 0.133 mg of aluminum, respectively in healthy adolescents aged 10 to 18 years (2 citation(s)) 263855/033 phase 3 Double-blind, randomised phase IIIb, study to compare the immunogenicity and reactogenicity of GSK Bios’ DTPa vaccine(Infanrix™)with GSK Bios’ dTpa (Boostrix™)administered to healthy children 4-6 years of age, having experienced an injection site reaction following the 4th dose of Infanrix™ vaccine (2 citation(s)) 263855/034 phase 4 Double-blind, randomized, phase III clinical trial to evaluate the immunogenicity and reactogenicity of three consecutive doses of dTpa, or of dTpa-IPV followed by two doses of Td vaccine , and compared to three consecutive doses of Td vaccine administered to healthy adults in a 0,1,6-month schedule (3 citation(s)) 263855/035 Phase 4 Phase IIIb study to evaluate immunogenicity, antibody persistency & reactogenicity of DTPa - INFANRIX & dTpa - BOOSTRIX vaccines admnd to healthy children previously primed with 3 doses of DTPa vaccine compared to placebo (HAVRIX®JUNIOR). (0 citation(s)) 263855/036 Phase 3 Open, phase IIIb, multicentric, safety and reactogenicity study of GSK Bios’ reduced antigen content combined diphtheria-tetanus-acellular pertussis vaccine admind as a booster dose to healthy children according to the international recomd prescribing information (3 citation(s)) 711866/001 Phase 3 A study to assess the lot-to-lot consistency of GSK Biologicals dTpa-IPV vaccine administered to healthy children 4 to 8 years of age, previously vaccinated with four doses of DTPa or DTPa-based combination vaccines and at least 3 doses of OPV or IPV (1 citation(s)) 711866/002 Phase 2 Phase II study to assess immunogenicity and reactogenicity of GSK Bios’ dTpa-IPV vaccine compared to GSK Bios’ dTpa and Aventis Pasteur Merck Sharp Dohme’s IPV vaccines admind separately,and to assess immunogenicity and reactogenicity of GSK Bios’ DTPa-IPV vaccine, when admind to healthy adolescents (3 citation(s)) 711866/003 phase 3 Assess immunogenicity, reactogenicity of GSK Biologicals’-dTpa-IPV vaccine versus dTpa & IPV vaccines administered separately & compared with Aventis Pasteur MSD’s Td-IPV vaccine when administered to healthy adolescents & adults (3 citation(s)) 711866/005 Phase 3 Open, 1-year, phase III, immunogenicity follow-up of subjects who previously received GSK Biologicals’ dTpa-IPV vaccine or GSK Biologicals’ dTpa (BoostrixTM) and Pasteur Mérieux’s IPV vaccine (IPV Mérieux() administered separately, at 4 to 8 years of age in study 711866/001 (dTpa-IPV-001) (1 citation(s)) 776423/001 phase 3 A phase III, observer-blinded randomised, multi-centre clinical study of the safety, immunogenicity and consistency of three manufacturing lots of GSK Bios’ candidate Tdap vaccine as compared to a US-licensed Td vaccine when given as a booster dose to healthy adolescents (10-18 years of age) (1 citation(s))
